Sensei Biotherapeutics files audited Faeth financials; net loss $16M in 2025, going-concern doubt

Sensei Biotherapeutics, Inc.

Faeth net loss $16.0M in 2025 ($18.3M in 2024); accumulated deficit $77.7M at Dec 31, 2025.
R&D expenses $12.0M (2025) vs $14.1M (2024); cash & equivalents $20.4M at Dec 31, 2025.
Auditor cites substantial doubt about going concern due to potential cash payments from $200M PIPE Series B preferred.
Acquisition of Faeth closed Feb 17, 2026; concurrent $200M PIPE closed Feb 20, 2026.

item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-157038
form_type: 8-K/A
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2026-04-15T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.047033+00:00
generated_at: 2026-05-15T06:09:41.933059+00:00
sec_items: ["9.01"]
event_type: m_and_a
sentiment: negative
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-157038
json_url: https://secwatch.observer/filing/0001193125-26-157038.json
markdown_url: https://secwatch.observer/filing/0001193125-26-157038.md
text_url: https://secwatch.observer/filing/0001193125-26-157038.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/0001193125-26-157038-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/d40329d8ka.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-157038

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.